Moderna Shares Surge After Positive Personalized Skin Cancer Trial Results
Moderna shares nearly trebled after the biotechnology company reported successful clinical results for personalized mRNA treatments targeting aggressive skin cancer, adding billions of dollars to its market value and drawing investor attention to the drugmaker’s pipeline.